Kathmere Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Kathmere Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$123K	Buy	+31,093	New	+$130K	0.01%	691

Other funds holding IRWD

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Range Financial Group Tigard, Oregon $361M AUM 58.71% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.66B AUM 22.28% 1-Year Est. Return

Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Kathmere Capital Management's IRWD Position: Q3 2026 in Review

Kathmere Capital Management opened a new position in Ironwood Pharmaceuticals (IRWD) in Q3 2026: 31,093 shares worth $123K. The stake represents 0.01% of the portfolio and ranks #691 among its holdings.

28 funds tracked by Wall St. Rank hold IRWD as of Q3 2026.

Kathmere Capital Management held 31,093 shares of Ironwood Pharmaceuticals worth $123K as of Q3 2026.
Ironwood Pharmaceuticals was a new Kathmere Capital Management position in Q3 2026.
Ironwood Pharmaceuticals made up 0.01% of Kathmere Capital Management's portfolio in Q3 2026, its #691 holding.
28 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2026.

Based on Kathmere Capital Management's 13F filing for Q3 2026, filed 20 Oct 2026.